FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3188556989> ?p ?o ?g. }

• W3188556989 endingPage "e788" @default.
• W3188556989 startingPage "e778" @default.
• W3188556989 abstract "BackgroundData are scarce on immunogenicity of COVID-19 vaccines in patients with autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to investigate the effect of different immunosuppressive drugs on antibody development after COVID-19 vaccination in patients with autoimmune diseases.MethodsIn this study, we used serum samples collected from patients with autoimmune diseases and healthy controls who were included in two ongoing prospective cohort studies in the Netherlands. Participants were eligible for inclusion in this substudy if they had been vaccinated with any COVID-19 vaccine via the Dutch national vaccine programme, which at the time was prioritising vaccination of older individuals. Samples were collected after the first or second COVID-19 vaccination. No serial samples were collected. Seroconversion rates and IgG antibody titres against the receptor-binding domain of the SARS-CoV-2 spike protein were measured. Logistic and linear regression analyses were used to investigate the association between medication use at the time of vaccination and at least until sampling, seroconversion rates, and IgG antibody titres. The studies from which data were collected are registered on the Netherlands Trial Register, Trial ID NL8513, and ClinicalTrials.org, NCT04498286.FindingsBetween April 26, 2020, and March 1, 2021, 3682 patients with rheumatic diseases, 546 patients with multiple sclerosis, and 1147 healthy controls were recruited to participate in the two prospective cohort studies. Samples were collected from patients with autoimmune diseases (n=632) and healthy controls (n=289) after their first (507 patients and 239 controls) or second (125 patients and 50 controls) COVID-19 vaccination. The mean age of both patients and controls was 63 years (SD 11), and 423 (67%) of 632 patients with autoimmune diseases and 195 (67%) of 289 controls were female. Among participants without previous SARS-CoV-2 infection, seroconversion after first vaccination were significantly lower in patients than in controls (210 [49%] of 432 patients vs 154 [73%] of 210 controls; adjusted odds ratio 0·33 [95% CI 0·23–0·48]; p<0·0001), mainly due to lower seroconversion in patients treated with methotrexate or anti-CD20 therapies. After the second vaccination, seroconversion exceeded 80% in all patient treatment subgroups, except among those treated with anti-CD20 therapies (three [43%] of seven patients). We observed no difference in seroconversion and IgG antibody titres between patients with a previous SARS-CoV-2 infection who had received a single vaccine dose (72 [96%] of 75 patients, median IgG titre 127 AU/mL [IQR 27–300]) and patients without a previous SARS-CoV-2 infection who had received two vaccine doses (97 [92%] of 106 patients, median IgG titre 49 AU/mL [17–134]).InterpretationOur data suggest that seroconversion after a first COVID-19 vaccination is delayed in older patients on specific immunosuppressive drugs, but that second or repeated exposure to SARS-CoV-2, either via infection or vaccination, improves humoral immunity in patients treated with immunosuppressive drugs. Therefore, delayed second dosing of COVID-19 vaccines should be avoided in patients receiving immunosuppressive drugs. Future studies that include younger patients need to be done to confirm the generalisability of our results.FundingZonMw, Reade Foundation, and MS Center Amsterdam." @default.
• W3188556989 created "2021-08-16" @default.
• W3188556989 creator A5001994531 @default.
• W3188556989 creator A5009731605 @default.
• W3188556989 creator A5012501139 @default.
• W3188556989 creator A5015927200 @default.
• W3188556989 creator A5018372157 @default.
• W3188556989 creator A5023265561 @default.
• W3188556989 creator A5024659677 @default.
• W3188556989 creator A5027096828 @default.
• W3188556989 creator A5027180965 @default.
• W3188556989 creator A5029733252 @default.
• W3188556989 creator A5037877175 @default.
• W3188556989 creator A5040227683 @default.
• W3188556989 creator A5041931606 @default.
• W3188556989 creator A5044831604 @default.
• W3188556989 creator A5049181172 @default.
• W3188556989 creator A5050087953 @default.
• W3188556989 creator A5056031703 @default.
• W3188556989 creator A5064574541 @default.
• W3188556989 creator A5066545631 @default.
• W3188556989 creator A5067384016 @default.
• W3188556989 creator A5078507054 @default.
• W3188556989 creator A5089238206 @default.
• W3188556989 creator A5090847445 @default.
• W3188556989 creator A5091662469 @default.
• W3188556989 date "2021-11-01" @default.
• W3188556989 modified "2023-10-17" @default.
• W3188556989 title "Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies" @default.
• W3188556989 cites W1513110336 @default.
• W3188556989 cites W1869015705 @default.
• W3188556989 cites W2022147863 @default.
• W3188556989 cites W2102990989 @default.
• W3188556989 cites W2104806243 @default.
• W3188556989 cites W2154652582 @default.
• W3188556989 cites W2154973129 @default.
• W3188556989 cites W2165601272 @default.
• W3188556989 cites W2262096914 @default.
• W3188556989 cites W2356862561 @default.
• W3188556989 cites W2792992921 @default.
• W3188556989 cites W3024016727 @default.
• W3188556989 cites W3097431453 @default.
• W3188556989 cites W3111255098 @default.
• W3188556989 cites W3111472711 @default.
• W3188556989 cites W3122628681 @default.
• W3188556989 cites W3127600917 @default.
• W3188556989 cites W3129660019 @default.
• W3188556989 cites W3131031601 @default.
• W3188556989 cites W3134648694 @default.
• W3188556989 cites W3139490202 @default.
• W3188556989 cites W3157552711 @default.
• W3188556989 cites W3158750369 @default.
• W3188556989 cites W3161839506 @default.
• W3188556989 cites W3162898139 @default.
• W3188556989 cites W3164513520 @default.
• W3188556989 cites W3173389157 @default.
• W3188556989 doi "https://doi.org/10.1016/s2665-9913(21)00222-8" @default.
• W3188556989 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8346242" @default.
• W3188556989 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34396154" @default.
• W3188556989 hasPublicationYear "2021" @default.
• W3188556989 type Work @default.
• W3188556989 sameAs 3188556989 @default.
• W3188556989 citedByCount "116" @default.
• W3188556989 countsByYear W31885569892021 @default.
• W3188556989 countsByYear W31885569892022 @default.
• W3188556989 countsByYear W31885569892023 @default.
• W3188556989 crossrefType "journal-article" @default.
• W3188556989 hasAuthorship W3188556989A5001994531 @default.
• W3188556989 hasAuthorship W3188556989A5009731605 @default.
• W3188556989 hasAuthorship W3188556989A5012501139 @default.
• W3188556989 hasAuthorship W3188556989A5015927200 @default.
• W3188556989 hasAuthorship W3188556989A5018372157 @default.
• W3188556989 hasAuthorship W3188556989A5023265561 @default.
• W3188556989 hasAuthorship W3188556989A5024659677 @default.
• W3188556989 hasAuthorship W3188556989A5027096828 @default.
• W3188556989 hasAuthorship W3188556989A5027180965 @default.
• W3188556989 hasAuthorship W3188556989A5029733252 @default.
• W3188556989 hasAuthorship W3188556989A5037877175 @default.
• W3188556989 hasAuthorship W3188556989A5040227683 @default.
• W3188556989 hasAuthorship W3188556989A5041931606 @default.
• W3188556989 hasAuthorship W3188556989A5044831604 @default.
• W3188556989 hasAuthorship W3188556989A5049181172 @default.
• W3188556989 hasAuthorship W3188556989A5050087953 @default.
• W3188556989 hasAuthorship W3188556989A5056031703 @default.
• W3188556989 hasAuthorship W3188556989A5064574541 @default.
• W3188556989 hasAuthorship W3188556989A5066545631 @default.
• W3188556989 hasAuthorship W3188556989A5067384016 @default.
• W3188556989 hasAuthorship W3188556989A5078507054 @default.
• W3188556989 hasAuthorship W3188556989A5089238206 @default.
• W3188556989 hasAuthorship W3188556989A5090847445 @default.
• W3188556989 hasAuthorship W3188556989A5091662469 @default.
• W3188556989 hasBestOaLocation W31885569891 @default.
• W3188556989 hasConcept C126322002 @default.
• W3188556989 hasConcept C159654299 @default.
• W3188556989 hasConcept C188816634 @default.
• W3188556989 hasConcept C197934379 @default.
• W3188556989 hasConcept C201903717 @default.
• W3188556989 hasConcept C203014093 @default.

• next